ストックスクリーナーアプリを入手
1.0096
1.02%
-0.0104
アフターアワーズ：
1.01
0.0004
+0.04%
前日終値:
$1.02
開ける：
$0.9801
24時間の取引高:
12,310
Relative Volume:
0.21
時価総額：
$36.52M
収益：
-
当期純損益:
$-8.53M
株価収益率:
-4.1479
EPS:
-0.2434
ネットキャッシュフロー:
$-12.75M
1週間 パフォーマンス:
-2.92%
1か月 パフォーマンス:
-7.80%
6か月 パフォーマンス:
-11.05%
1年 パフォーマンス:
+14.73%
1日の値動き範囲:
$0.97
$1.0197
1週間の範囲:
$0.94
$1.05
52週間の値動き範囲:
$0.63
$3.23
Estrella Immunopharma Inc Stock (ESLA) Company Profile
名前
Estrella Immunopharma Inc
セクター
電話
(510) 318-9098
住所
5858 HORTON STREET, SUITE 370, EMERYVILLE
ESLA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
1.0096 | 37.61M | 0 | -8.53M | -12.75M | -0.2434 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Estrella Immunopharma Inc (ESLA) 最新ニュース
Estrella Immunopharma’s (ESLA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial - Yahoo
ESLA Stock Rating and Price Target Maintained by D. Boral Capita - GuruFocus
Estrella Immunopharma, Inc. Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com
Estrella Immunopharma Advances STARLIGHT-1 Clinical Trial - TipRanks
ESLA Stock Rating and Price Target Maintained by D. Boral Capital | ESLA Stock News - GuruFocus
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com
Estrella Immunopharma (ESLA) Advances in Phase I/II STARLIGHT-1 Trial | ESLA Stock News - GuruFocus
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas - Yahoo Finance
Geode Capital Management LLC Acquires 16,862 Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) - Defense World
ESLA Stock: A Voyage Through Estrella Immunopharma Inc’s Finances - investchronicle.com
A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners - BioSpace
Estrella Immunopharma completes first dose cohort in STARLIGHT trial - Yahoo Finance
Sector Update: Health Care -February 21, 2025 at 03:42 pm EST - Marketscreener.com
Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study - Marketscreener.com
Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose Cohort - Marketscreener.com
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort - The Bakersfield Californian
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital - 01net
Estrella Immunopharma (NASDAQ:ESLA) Now Covered by Analysts at D. Boral Capital - Defense World
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Estrella Immunopharma regains Nasdaq compliance - Investing.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Quotes, Forecast and News Summary - Benzinga
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Estrella Immunopharma extends stock sale agreement with White Lion By Investing.com - Investing.com Canada
Estrella Immunopharma faces Nasdaq delisting over equity shortfall - Investing.com
Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider - Simply Wall St
Eureka Therapeutics Tackling Advanced Hepatocellular Carcinoma With T-Cell Therapy ECT204 in Phase 1/2 ARYA-3 Clinical Trial - CGTLive™
Estrella Immunopharma Appoints Dr. Cheng Liu as CEO - TipRanks
Tesla stock hits 52-week low at $0.75 amid market challenges - Investing.com
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™
First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive®
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells - BioSpace
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member - Business Wire
Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas Doses First Patient - CGTLive®
Wall Street today: US stocks trade higher after promising inflation data raises Fed rate cut bets; 3M Co. gains 18.99% - Mint
OS Therapies (AMEX:OSTX) Stock Quotes, Forecast and News Summary - Benzinga
Estrella Immunopharma streamlines operations with subsidiary merger - Investing.com India
Laura Franco - Mintz
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances - InvestorPlace
Excision Seeks to Suppress HIV Viral Replication With EBT-101 CRISPR Gene Therapy - CGTLive™
Direct Biologics’ Phase 1 Clinical Trial Seeks to Treat Crohn Disease With Extracellular Vesicles - CGTLive™
Tenaya's Phase 1b MyPeak-1 Trial is Testing the Waters in Gene Therapy for Hypertrophic Cardiomyopathy - CGTLive™
ESLAEstrella Immunopharma Latest Stock News & Market Updates - StockTitan
ESLA Stock Price and Chart — NASDAQ:ESLA - TradingView
Estrella Immunopharma nears completion of SPAC listing - Bamboo Works
Calidi Biotherapeutics (AMEX:CLDI) Stock Quotes, Forecast and News Summary - Benzinga
Estrella and TradeUP merge to become publicly traded company - Labiotech.eu
Manufacturing Stocks Investing - MarketBeat
PepGen (NASDAQ:PEPG) Stock Quotes, Forecast and News Summary - Benzinga
TradeUP Acquisition (UPTD) Stock Price, News & Analysis - MarketBeat
Estrella Immunopharma Inc (ESLA) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):